Introduction {#Sec1}
============

Non-alcoholic steatohepatitis (NASH) is a chronic and progressive liver disease characterized by the accumulation of fat in the liver (steatosis), as well inflammation \[[@CR1], [@CR2]\]. NASH is a progression of non-alcoholic fatty liver disease (NAFLD), an umbrella term to describe excess fat in the liver of patients who drink little to no alcohol \[[@CR1]\]. The exact cause of NAFLD to NASH progression is unknown and is likely due to a complex interplay of environmental and genetic factors; however, certain health conditions, such as obesity, high blood pressure and diabetes, increase the risk of it developing \[[@CR3], [@CR4]\]. Numerous genetic, epigenetic and environmental contributors have recently been proposed as the cause of NAFLD and NASH, including smoking and altered copper bioavailability \[[@CR5]--[@CR7]\].

NASH is often inaccurately described as an asymptomatic disease \[[@CR8]\]---it presents with non-specific symptoms, such as tiredness or developing pain in the upper right side of the abdomen, therefore the disease can progress undetected \[[@CR3]\]. This makes the exact burden difficult to establish. However, NASH burden is increasing, parallelled by the rise of obesity and NAFLD, with an estimated one-third of NAFLD patients progressing into NASH \[[@CR1]\]. In the UK alone, this represents approximately 5% of the population \[[@CR9], [@CR10]\]. NASH can lead to liver fibrosis, with approximately 20% of all NASH patients suffering from advanced fibrosis---namely bridging fibrosis (F3) or cirrhosis (F4) \[[@CR1], [@CR11]\]. Advanced fibrosis increases the disease burden in NASH significantly, leading to end-stage liver disease, hepatocellular cancer (HCC), liver transplantation and death \[[@CR12]\]. The underlying fibrosis stage is key in determining clinical outcomes and mortality, with advanced fibrosis being an independent predictor of overall and disease-specific mortality \[[@CR13]\].

Despite its growing burden, there is a lack of effective non-invasive diagnosis tests for NASH \[[@CR14]\]. Liver biopsy is often considered the current gold standard for diagnosis in spite of challenges associated with its accuracy, patient acceptance, safety and cost. In addition to its complex nature and difficulties in diagnosing, there are currently no approved therapies for NASH \[[@CR14]--[@CR16]\]. Understanding the epidemiology and burden of NASH is vital in establishing clear guidelines for early detection and effective therapies \[[@CR17]\].

The current evidence base for the epidemiology and burden of disease (BoD) of NASH is very limited, with few systematic literature reviews (SLRs) available and NASH frequently reported as part of the wider NAFLD burden. To understand the unmet need in NASH, this structured literature review aimed to examine the current knowledge on NASH epidemiology and BoD, focusing on the prevalence, comorbidities, disease progression, mortality, quality of life (QoL) and economic burden. The primary objective was to understand the NASH epidemiology landscape, encompassing the broad overarching societal and economic impacts on both the individual and the healthcare system, and to identify key gaps in current knowledge to inform future research.

Methodology {#Sec2}
===========

A structured literature review was performed according to an agreed search protocol following the systematic principles of the Cochrane handbook for systematic reviews \[[@CR18]\]. The following electronic databases were searched utilizing the Ovid search engine: Embase, Medline, PsycINFO and EconLit. Two independent literature searches were conducted to identify publications relating to the epidemiology and BoD of NASH. The search terms used in the search strategy utilized a combination of free-text searching and 'subject headings' to ensure that the most relevant literature was identified for review. The full search strategy is presented in Appendix A. Searches were limited to English language publications between January 2007 and September 2017.

Publications were included in the full-text review if they reported on disease burden, disease progression, epidemiology, humanistic burden, healthcare utilization or economic burden in adults with NASH only. As a result of the breadth of our overarching objectives to critique and understand epidemiological and BoD aspects of NASH, the specific detail of individual therapy and management options was not a consideration for inclusion criteria and evaluation in this review. In addition to NASH-focused publications, data from NAFLD-focused publications were included in this review if the reported patient population was stratified into discrete NASH and NAFLD populations, and results were reported in sufficient detail that the NASH results could be inferred or calculated.

An internet-based search using a combination of keywords was also conducted to ensure that the latest relevant abstracts and publications were captured. The search included both non-peer-reviewed publicly available information and peer-reviewed publications that may not yet be indexed in databases such as PUBMED or Embase, because of their recent publication date, or because they were published in journals that are not indexed within these databases. A grey literature search was also carried out, reviewing conference proceedings from International Society for Pharmacoeconomics and Outcomes Research (ISPOR), American Association for the Study of Liver Diseases (AASLD), European Association for the Study of Diabetes (EASD), European Association for the Study of the Liver (EASL), Paris Hepatology Conference (PHC) and 3rd Paris NASH Symposium.

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Results {#Sec3}
=======

During the title and abstract screening, 1229 of the 1273 retrieved abstracts were excluded on the basis of defined inclusion criteria presented in the preceding section. The full text of 44 potentially relevant records was assessed and six records were excluded. The grey literature search identified 15 conference abstracts/posters and guidelines, which were deemed relevant for inclusion. In total, 53 publications (38 full-text and 15 grey literature sources) were included into the evidence base used to develop this review. A full Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram is presented in Fig. [1](#Fig1){ref-type="fig"}. The publications were categorized on the basis of the type of BoD data reported as follows: NASH prevalence and incidenceComorbidities associated with NASHDisease progression and mortality in NASH patientsNASH QoLNASH economic burdenFig. 1PRISMA diagram of included and excluded publications

The majority of the 53 included publications were small cohort studies and narrative reviews. Several SLRs and economic models and evaluations were also reported (Fig. [2](#Fig2){ref-type="fig"}). The full list of captured publications is presented in Appendix B.Fig. 2Publications captured in the literature review by study type.*PRO* patient-reported outcomes,*RCT* randomized controlled trial,*SLR* systematic literature review

NASH Prevalence and Incidence {#Sec4}
-----------------------------

The overall NASH prevalence was reported in 13 publications \[[@CR19]--[@CR31]\]. NASH was estimated to affect between 3% and 5% of the global population, with minor variation at the country-specific level; prevalence data were captured for the Chinese, Japanese, UK and USA populations (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Overall NASH prevalence in the general population.*NASH* non-alcoholic steatohepatitis,*UK* United Kingdom,*USA* United States. ^a^Values rounded to 1 decimal point

Over half of the publications primarily focused on the NAFLD population and employed a narrative review approach. The research focus varied across publications and different methodologies were used to determine NASH epidemiology; therefore, direct comparison of prevalence data was difficult. Of note, only four of the 13 prevalence publications specified the exact methodology. One population-based study used a validated histological 'NASH' score to estimate the NASH prevalence. The remaining three publications used data from annual health checks, national health surveys and autopsy results to estimate the prevalence of NASH \[[@CR24], [@CR26], [@CR28], [@CR29]\].

The epidemiology of NASH was reported in an SLR and meta-analysis which collated data from the USA, UK, France, Germany and Italy \[[@CR19]\]. By computing the incidence, mortality and disease transition probability parameters in a series of interlinked Markov chains, it reported that the majority of NASH patients exhibit NASH without fibrosis (approximately 67%), while up to 25% and 11% had fibrosis and cirrhosis, respectively \[[@CR19]\]. These were also most common in the 65+ age group, highlighting the progressive increase in disease burden in NASH \[[@CR19]\].

Although NASH prevalence was reported frequently in the captured publications, no incidence data for NASH were found, highlighting a data gap.

### The NAFLD/NASH Continuum {#Sec5}

While several NAFLD-focused publications reported NASH prevalence in the general population, one publication reported on NAFLD-specific NASH prevalence \[[@CR19]\]. In this SLR and meta-analysis, approximately 60% of biopsied NAFLD patients (95% confidence interval (CI) 47.55--69.73) progressed to NASH \[[@CR19]\]. However, the authors acknowledged there may be a selection and ascertainment bias in this estimate since indication for biopsy is typically conducted in NAFLD patients with a high risk of progressing to NASH. Further stratification of NASH prevalence was available for NAFLD patients with and without an indication for biopsy across Asia, Europe (EU) and North America. Although NASH prevalence was similar across regions (ranging from 63% to 69%), NASH was over four times more prevalent in NAFLD patients without indication for biopsy in North America (29.85%; 95% CI 22.72--38.12) compared to Asia (6.67%; 95% CI 2.17--18.73) \[[@CR19]\].

Comorbidities Associated with NASH {#Sec6}
----------------------------------

Comorbidity data were the most frequently reported, with 18 publications describing obesity, diabetes and cardiovascular comorbidities in NASH patients (Table [1](#Tab1){ref-type="table"}) \[[@CR19], [@CR21], [@CR22], [@CR24], [@CR28]--[@CR30], [@CR32]--[@CR42]\].Table 1NASH and comorbidities prevalenceReferencesTypeCountryTotal study size (*n*)Adult populationPrevalence (%)**NASH prevalence**Lall et al. \[[@CR28]\]Narrative reviewUSANot reportedNASH in obese patients15--30Mummadi et al. \[[@CR33]\]Meta-analysisUSA766NASH in obese patients18.5NASH in morbidly obese patients33Estep et al. \[[@CR43]\]Cohort study abstractNot reported44NASH in obese bariatric surgery patients75Hyysalo et al. \[[@CR24]\]Population-based prevalence studyFinland676NASH in obese bariatric surgery patients aged 45--7414.5NASH in diabetic bariatric surgery patients aged 45--7417Athyros et al. \[[@CR21]\]Narrative reviewGlobalNot reportedNASH in morbidly obese patients37Losekann et al. \[[@CR32]\]Retrospective cohort studyBrazil250NASH in morbidly obese patients70.4Sanyal et al. \[[@CR30]\]SLR abstractGlobalNot reportedNASH in obese bariatric surgery patients34--94Sayiner et al. \[[@CR29]\]Narrative reviewGlobalNot reportedNASH in obese bariatric surgery patients33.6--37Joshi et al. \[[@CR41]\]Retrospective study abstractUSA1920NASH in type 2 diabetic patients38Institute for Clinical and Economic Review \[[@CR42]\]Evidence review and comparative clinical effectiveness analysisUSANot reportedNASH in type 2 diabetic patients63--87**Obesity prevalence**Younossi et al. \[[@CR19]\]SLR and meta-analysisGlobal8,515,431Obesity in NASH patients81.8^a^EUObesity in NASH patients89.2^a^OceaniaObesity in NASH patients95.2^a^South AmericaObesity in NASH patients45.5^a^North AmericaObesity in NASH patients without indication for biopsy80Sanyal et al. \[[@CR30]\]SLR abstractGlobalNot reportedObesity in NASH patients31--89**Type 2 diabetes prevalence**Promrat et al. \[[@CR40]\]RCTUSA31Type 2 diabetes in NASH48Simons et al. \[[@CR39]\]Cohort study abstractUSA324Type 2 diabetes in NASH LT patients77VanWagner et al. \[[@CR38]\]Cohort study abstractUSA6932Type 2 diabetes in NASH LT patients46.2Estep et al. \[[@CR43]\]Cohort study abstractNot reported44Type 2 diabetes in obese NASH bariatric surgery patients20.3^b^McPherson et al. \[[@CR35]\]Cohort studyUK448Type 2 diabetes in NASH56VanWagner et al. \[[@CR37]\]Database analysisUSA5057Type 2 diabetes in NASH LT patients57.1Losekann et al. \[[@CR32]\]Retrospective cohort studyBrazil250Type 2 diabetes in morbidly obese diabetic NASH patients9^c^Younossi et al. \[[@CR19]\]SLR and meta-analysisGlobal8,515,431Type 2 diabetes in NASH43.6^a^Mantry et al. \[[@CR36]\]Retrospective study abstractUSA650Type 2 diabetes in NASH45Sanyal et al. \[[@CR30]\]SLR abstractUSANot reportedType 2 diabetes in NASH5.3--73.1**CVD prevalence**Vilar-Gomez et al. \[[@CR34]\]Prospective cohort studyCubaNot reportedCVD in NASH patients2Barritt et al. \[[@CR44]\]Observational studyUSA1441CVD in NASH patients9.4^d^**Hyperlipidaemia prevalence**Estep et al. \[[@CR43]\]Cohort study abstractNot reported44Hyperlipidaemia in obese NASH bariatric surgery patients23.3^e^Vilar-Gomez et al. \[[@CR34]\]Prospective cohort studyCubaNot reportedHyperlipidaemia in NASH patients52Younossi et al. \[[@CR19]\]SLR and meta-analysisGlobal8,515,431Hyperlipidaemia in NASH patients72.1^a^Sanyal et al. \[[@CR30]\]SLR abstractUSANot reportedHyperlipidaemia in NASH patients16.9--86.2**Hypertension prevalence**Estep et al. \[[@CR43]\]Cohort study abstractNot reported44Hypertension in obese NASH bariatric surgery patients28.5^f^VanWagner et al. \[[@CR37]\]Database analysisUSA5057Hypertension in NASH LT patients35.7Younossi et al. \[[@CR19]\]SLR and meta-analysisGlobal8,515,431Hypertension in NASH patients68^a^Sanyal et al. \[[@CR30]\]SLR abstractUSANot reportedHypertension in NASH patients20.2--85.7**Metabolic syndrome prevalence**Hyysalo et al. \[[@CR24]\]Population-based prevalence studyFinland676Metabolic syndrome in NASH bariatric surgery patients aged 45--743.4^g^Merola et al. \[[@CR22]\]Clinical reviewUSANot reportedMetabolic syndrome in NASH LT patients40--60Younossi et al. \[[@CR19]\]SLR and meta-analysisGlobal8,515,431Metabolic syndrome in NASH patients70.7^a^Sanyal et al. \[[@CR30]\]SLR abstractUSANot reportedMetabolic syndrome in NASH patients7.5--92.7**Hypercholesterolaemia prevalence**Sanyal et al. \[[@CR30]\]SLR abstractUSANot reportedHypercholesterolaemia in NASH patients90.2**Hypertriglyceridaemia prevalence**Younossi et al. \[[@CR19]\]SLR and meta-analysisGlobal8,515,431Hypercholesterolaemia in NASH patients40.7^a^*CVD* cardiovascular disease, *EU* Europe, *LT* liver transplant, *NASH* non-alcoholic steatohepatitis, *RCT* randomized controlled trial, *SLR* systematic literature review, *UK* United Kingdom, *USA* United States^a^Values rounded to 1 decimal point^b^Calculated 27 × 0.75 = 20.3%, based on 75% of the population being NASH obese patients with bariatric surgery^c^Calculated 12.8 × 0.704 = 9%, based on 70.4% of the population being NASH morbidly obese patients^d^Calculated 20 × 0.47 = 9.4%, based on 47% of the population being diagnosed with NASH^e^Calculated 31 × 0.75 = 23.3%, based on 75% of the population being NASH obese patients with bariatric surgery^f^Calculated 38 × 0.75 = 28.5%, based on 75% of the population being NASH obese patients with bariatric surgery^g^Calculated 57 × 0.06 = 3.4, based on 6% of the population being diagnosed with NASH

Overall, the prevalence of comorbidities associated with NASH was high, indicating a high disease burden and the burden of clinical management \[[@CR19]\]. There was huge variability in the focus of the publications: some publications described the overall NASH population, whilst others focused on specific sub-populations, such as obese, diabetic, liver transplant (LT) and bariatric surgery patients. Consequently, findings were described as either a comorbidity prevalence in NASH or NASH prevalence in the comorbid sub-populations and, as such, a broad range of prevalence was reported. Variations in study methodologies meant that it was not possible to establish the correlation between these two types of prevalence reported; therefore, both are presented here (Table [1](#Tab1){ref-type="table"}).

Risk factors for developing NASH were also reported, with female gender, over 50 years of age, diabetes, obesity, hyperlipidaemia/dyslipidaemia, hypertriglyceridaemia, metabolic syndrome and hypertension being reported as specific factors increasing the risk of NASH \[[@CR19], [@CR22], [@CR26], [@CR29], [@CR35]\].

### Obesity {#Sec7}

The obesity prevalence in the NASH population was reported in two publications, ranging from 31% to 95% (Table [1](#Tab1){ref-type="table"}) \[[@CR19], [@CR30]\]. An SLR with a meta-analysis estimated that 82% of NASH patients suffer from obesity, with another SLR in broad agreement (estimated prevalence was between 31% and 89%); however, the authors cautioned that this range is likely influenced by the variable case definitions and methods used in individual studies examined in this review \[[@CR19], [@CR30]\]. Obesity prevalence in NASH was also reported in different geographical regions, with obesity being twice as prevalent in NASH patients in the EU (89.19%, 95% CI 74.51--95.88) and Oceania (95.24%, 95% CI 82.86--98.81) compared to South America (45.45%, 95% CI 26.47--65.86) \[[@CR19]\].

NASH prevalence in the obese population was reported in seven publications and was more fragmented compared to obesity prevalence in NASH, largely due to the different populations of focus in the relevant publications (such as morbidly obese, obese, or bariatric surgery patients) \[[@CR21], [@CR24], [@CR28]--[@CR30], [@CR32], [@CR33]\]. NASH prevalence ranged from 15% to 94%, depending on the population examined (Table [1](#Tab1){ref-type="table"}), with prevalence in obese and morbidly obese patients reported as 15--30% and 33--70%, respectively \[[@CR21], [@CR28], [@CR33]\]. NASH prevalence in the obese population with bariatric surgery was between 34% and 94% \[[@CR29], [@CR30]\]. Obese prevalence data were frequently reported for the global or USA populations, with one publication each focusing on Finnish and Brazilian NASH populations \[[@CR24], [@CR32]\].

### Type 2 Diabetes {#Sec8}

Type 2 diabetes prevalence in NASH was reported in ten publications \[[@CR19], [@CR30], [@CR32], [@CR35]--[@CR40], [@CR43]\]. An SLR and meta-analysis estimated the global diabetes prevalence among NASH patients to be 43.6% (Table [1](#Tab1){ref-type="table"}) \[[@CR19]\]. Similar results were presented in cohort studies (ranging between 33% and 56%) \[[@CR34]--[@CR36]\]. Another SLR reported a broader estimate of between 5% and 73%; however, similarly to the obese population, the authors cautioned that the variable methods used in the captured studies have likely influenced these results \[[@CR30]\]. The prevalence of diabetes was also reported in NASH LT patients and ranged between 46% and 77%, suggesting an increased burden of diabetes LT patients \[[@CR37]--[@CR39]\].

NASH prevalence in the diabetic population was reported in three publications, ranging from 18% to 87% \[[@CR24], [@CR41], [@CR42]\]. Although the NASH prevalence was higher in diabetics alone compared to diabetic bariatric surgery patients, the research focus of the captured publications varied substantially in terms of the geography, with two publications focusing on the USA and one on Finland, and the type of population, such as NASH diabetic and NASH diabetic bariatric surgery patients, therefore making further meaningful comparisons impossible.

### Cardiovascular Disease {#Sec9}

Eight publications reported the prevalence of cardiovascular comorbidities in NASH patients, specifically focusing on hypercholesterolaemia, hyperlipidaemia, hypertension and metabolic syndrome (Table [1](#Tab1){ref-type="table"}) \[[@CR19], [@CR22], [@CR24], [@CR30], [@CR34], [@CR37], [@CR43], [@CR44]\]. Only two publications reported the overall cardiovascular disease (CVD) prevalence among NASH patients, which ranged from 2% to 20% \[[@CR34], [@CR44]\]. A large SLR and meta-analysis reported the overall pooled prevalence for cardiovascular comorbidities among NASH patients as 72% for hyperlipidaemia/dyslipidaemia, 41% for hypertriglyceridaemia, 68% for hypertension and 71% for metabolic syndrome \[[@CR19]\]. This was in broad agreement with the wide range of prevalence (from 7.5% to 92.7%) reported in another SLR \[[@CR30]\]. Other publications reported a range of prevalence estimates, in line with the varying methodologies and population focus of the publications \[[@CR22], [@CR24], [@CR34], [@CR37], [@CR43]\]. Small cohort studies and narrative reviews reported lower prevalence, specifically in sub-populations, such as NASH LT patients and NASH bariatric surgery patients \[[@CR22], [@CR24], [@CR34], [@CR37], [@CR43]\]. As a result of fragmentation of the data and the less robust methodologies employed by these studies, no further conclusions could reliably be drawn.

Disease Progression and Mortality in NASH Patients {#Sec10}
--------------------------------------------------

Disease progression and mortality was reported in 24 publications; fibrosis data were the most frequently reported, followed by cirrhosis and HCC \[[@CR19]--[@CR23], [@CR26]--[@CR28], [@CR35], [@CR37], [@CR45]--[@CR58]\]. Half of the publications were narrative reviews, while the other half ranged from small cohort studies to SLRs, highlighting a substantial range in the robustness of the data reported.

### Disease Progression in NASH {#Sec11}

As a result of a lack of effective diagnostic tools and nonspecific symptoms, NASH progression was difficult to establish. The majority of the publications did not specify the methodologies used to confirm disease progression; only a few utilized liver biopsies \[[@CR19], [@CR28], [@CR46], [@CR47]\].

The captured literature reported that up to 44% of patients with steatosis progress to NASH \[[@CR23], [@CR35]\]. While early stages of NASH can be bidirectional (i.e. progression and regression can occur), the majority of patients (93%) did not regress back to earlier stages of fibrosis (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR35]\].Fig. 4NASH disease progression. *F0/4* fibrosis stage 0/4, *HCC* hepatocellular carcinoma, *NASH* non-alcoholic steatohepatitis.Data adapted from Traussnigg et al. \[[@CR45]\]

#### Fibrosis Progression in NASH {#Sec12}

Several studies examining liver biopsy reported that approximately 40% of NASH patients progress to fibrosis globally \[[@CR19], [@CR28], [@CR46], [@CR47]\]. Global average annual progression of NASH to fibrosis was twice as fast as non-alcoholic fatty liver (NAFL) progression, corresponding to an average progression by one stage over 7.1 years versus 14.3 years, and highlighting the increase in the patient burden of NASH compared to NAFLD \[[@CR23], [@CR47]\].

An SLR of risk factors for fibrosis progression highlighted that the rate of progression increases in fibrosis patients compared to the overall NASH cohort, from 0.03 stages/year to 0.41 stages/year, respectively \[[@CR46]\]. Inflammation on initial biopsy had a strongly significant predictive value for development of advanced fibrosis (*p* \< 0.0001), with median time to progression to advanced fibrosis in patients with inflammation being 4.2 years versus 13.4 years in patients without inflammation \[[@CR46]\].

In long-term follow-up over 5.3 years, most patients experienced no change in NASH severity; however, of the patients who did progress, approximately 70% advanced one stage and approximately 32% progressed two or more stages \[[@CR46]\]. The authors concluded that between 5% and 10% of patients with NASH diagnosed on their initial biopsy will present with clinically significant fibrosis at this initial biopsy, and an additional 15--20% will progress to advanced fibrosis in less than a decade, emphasizing the progressive burden of NASH advanced fibrosis \[[@CR46]\].

Progression between NASH fibrosis stages was also described in the evidence base. Progression between any fibrosis stages was reported in 16--71% of NASH patients, progression from F1/F2 onwards in 9--13%, and from F3 onwards in 9--25% of patients (Table [2](#Tab2){ref-type="table"}) \[[@CR19], [@CR23], [@CR46], [@CR49], [@CR53], [@CR54]\]. It is important to highlight that the publications reporting fibrosis stage progression utilized different stage terminology, e.g. F0--F4, stage 1/4, progressive fibrosis, advanced fibrosis, severe fibrosis, etc. The definitions for these stages were not always clarified; therefore, the comparability of these results was limited.Table 2NASH progression to fibrosisReferencesTypeCountryTotal study size (*n*)NASH stageProgression (%)**Progression from NASH to fibrosis**Argo et al. \[[@CR46]\]SLRUSA221All NASH patients to stage 3/4 fibrosis15.8% over 3.7 years (mean interval)NASH fibrosis patients who progressed to stage 3/4 fibrosis42.1% over 3.7 years (mean interval)Musso et al. \[[@CR49]\]Meta-analysisNot reportedNot reportedNASH to progressive fibrosis25--30% over 4 years50% over 6 yearsSporea et al. \[[@CR54]\]Retrospective cohort studyRomania478NASH to severe fibrosis18.5%^a^NASH to no severe fibrosis70.8%^a^Satapathy et al. \[[@CR23]\]Narrative reviewUSANot reportedNASH to fibrosis37%^a^NASH to F3 fibrosis22%^a^NASH to progressive fibrosis34.5%^a^Younossi et al. \[[@CR19]\]SLRUSA8,515,431NASH to fibrosis41%^a^Shouhed et al. \[[@CR53]\]Narrative reviewUSANot reportedNASH to fibrosis26--57%^a^**Progression from F1/F2 fibrosis onwards**Musso et al. \[[@CR49]\]Meta-analysisSwedenNot reportedF1/2 fibrosis to cirrhosis13%^a^**Progression from F3 fibrosis onwards**Musso et al. \[[@CR49]\]Meta-analysisSwedenNot reportedF3 fibrosis to cirrhosis and end stage liver disease25%^a^Shouhed et al. \[[@CR53]\]Narrative reviewUSANot reportedFibrosis to cirrhosis9--17%^a^*F1/2/3/4* fibrosis stage 1/2/3/4, *NASH* non-alcoholic steatohepatitis, *SLR* systematic literature review, *USA* United States^a^Time frame not reported

#### Cirrhosis and HCC Progression in NASH {#Sec13}

Cirrhosis and HCC progression were reported in ten publications \[[@CR19], [@CR20], [@CR22], [@CR23], [@CR26], [@CR27], [@CR45], [@CR50], [@CR51], [@CR55]\]. In the captured publications, up to 25% of NASH patients progressed to liver cirrhosis and HCC \[[@CR20], [@CR22], [@CR27], [@CR45]\].

The prevalence of cirrhosis progression was reported as significantly higher in NASH patients compared to NAFL patients (10.8% versus 0.7%, respectively) \[[@CR50]\]. A model of simulated NASH patient life course examined the average time of progression to decompensated cirrhosis and HCC for every NASH fibrosis stage, and the simulated average time to progress from early stage fibrosis (F1/F2) was longer (approximately 16 years) than the time to progress from advanced fibrosis (approximately 10 years) \[[@CR55]\]. This highlighted the long-term clinical outcomes and increased mortality risk related to NASH progression \[[@CR55]\].

HCC incidence was reported in three publications; however, this was reported as three distinct types of incidence: global cumulative incidence (2.4% over 7 years and 12.8% over 3 years), global annual incidence \[5.29 per 1000 patient years (95% CI 0.75--37.56)\] and incidence in Japan (between 5% and 25% during approximately 7 years) \[[@CR23], [@CR26]\]. As the incidence type varied between publications, no robust comparisons could be made across these data.

An increased burden of NASH progression was acknowledged, highlighting that the rate of HCC progression is expected to increase faster than other hepatic diseases, such as hepatitis B or C. Consequently there are important implications for resource utilization, given that HCC has emerged as the sixth most common cancer and second leading etiology of cancer-related deaths worldwide \[[@CR19]\]. A healthcare utilization model was in accord with this, predicting a disproportionate increase in NASH by 2030: the prevalences of compensated and decompensated cirrhosis cases were projected to increase 180% and 200% from 2015 to 2030, respectively \[[@CR51]\]. The number of NASH-related HCC cases was also projected to reach 12,220 cases in 2030, an increase of approximately 140% compared to 2015 \[[@CR51]\].

### Mortality in NASH {#Sec14}

Fifteen publications reported mortality outcomes in NASH patients \[[@CR20]--[@CR23], [@CR26], [@CR28], [@CR37], [@CR46], [@CR48]--[@CR50], [@CR55]--[@CR58]\]. Several publications outlined an increased risk of death in NASH compared to the general population and patients with NAFL, and decreased survival compared to NAFLD patients \[[@CR20], [@CR28], [@CR48], [@CR49]\].

The overall mortality rate in NASH was 25.56 per 1000 patient years, with the liver-specific mortality rate reported as 11.77 per 1000 patient years \[[@CR20]\]. An SLR and meta-analysis reported liver disease as the main cause of death in NASH, with a liver-related mortality rate of 11--17.5% compared to 1.7--2.7% of NAFLD (pooled odds ratio (OR) 5.71; 95% CI 2.31--14.13; *p* = 0.0002) \[[@CR49]\]. However, this was disputed in several narrative reviews, which reported CVD and malignancies as the main cause of death in NASH patients \[[@CR20], [@CR23], [@CR57]\]. These publications reported the cause of death using several different measurements and across different populations; therefore, a selection bias may have been present.

#### NASH Fibrosis Mortality {#Sec15}

There was a significant worsening of mortality outcomes reported with advanced fibrosis (F3/F4) in NASH. Fibrosis progression was linked to a 70% increase in total mortality, compared with patients without fibrosis \[[@CR21]\]. NASH patients with moderate-to-severe fibrosis at baseline also showed a worse survival rate compared to patients with mild fibrosis or no fibrosis (adjusted hazard ratio (HR) 2.09, *p* = 0.01) \[[@CR21]\].

In addition, a model on the life course of NASH patients predicted that the long-term liver-related mortality and survival in NASH is worsened with fibrosis progression over 15 years \[[@CR55]\]. This aligned with a previously conducted SLR and meta-analysis, which showed that advanced fibrosis increases liver-related mortality almost fivefold compared to mild fibrosis \[[@CR49]\].

#### NASH Cirrhosis and HCC Mortality {#Sec16}

An increased mortality burden was also reported with NASH cirrhosis. NASH cirrhosis patient life expectancy was lower than non-cirrhotic NASH patients, with cirrhotic patients' survival ranging from 59% to 84% of the life expectancy of those without cirrhosis \[[@CR26], [@CR46], [@CR50]\]. Median survival in NASH cirrhosis patients was approximately 6 years; they had a similar liver-related mortality compared to viral cirrhosis and a higher CVD-related mortality was observed \[[@CR49]\]. Annual mortality rates for patients with compensated cirrhosis and decompensated cirrhosis specifically were 2% and 13%, respectively, demonstrating a higher mortality burden with progressive worsening of cirrhosis \[[@CR58]\].

There was a paucity of HCC mortality data, reported in only two publications \[[@CR26], [@CR50]\]. The 5-year survival of NASH HCC was reported as 44.8%, with HCC being one of the leading causes of death in NASH patients (47% of deaths), representing an independent risk factor for liver-related mortality (HR 7.96) \[[@CR26], [@CR50]\].

NASH QoL {#Sec17}
--------

There was a paucity of data reporting on QoL, specifically on patient-reported outcomes (PRO), with only three publications identified \[[@CR59]--[@CR61]\]. The following experiences were captured in the search: only one generic PRO instrument, the Short Form-36 (SF-36) health survey and one liver-specific questionnaire, the Chronic Liver Disease Questionnaire (CLDQ) reported BoD data \[[@CR59]--[@CR61]\].

Two publications reported on NASH patients experiencing poorer physical and mental health compared to non-NASH patients according to the SF-36 scale, with significantly poorer scores in NASH patients compared to non-NASH patients in mental health, physical functioning, role limitations due to emotional health and social function (*p* \< 0.05 for all) \[[@CR59], [@CR60]\]. These findings were confirmed via the CLDQ instrument, which revealed additional impairments in all domains (abdominal symptoms, fatigue, systemic symptoms, activity, emotional function, worry) associated with a reduced overall CLDQ score (*p* \< 0.0001 for all) \[[@CR60], [@CR62]\]. The presence of diabetes \[*p* = 0.04 for Physical Component Score (PCS)\] was the only demographic/clinical variable reported that was associated with impaired health-related quality of life (HRQoL) amongst NASH patients \[[@CR60]\]. The authors concluded that CLDQ was a reliable and valid measurement tool of disease-specific HRQoL in adults with NASH.

NASH Economic Burden {#Sec18}
--------------------

NASH economic burden was reported in 12 publications \[[@CR30], [@CR42], [@CR58], [@CR63]--[@CR70]\].

The majority of the publications were health economic evaluations, with the cost-effectiveness of NASH screening methods and treatments the most reported-on economic outcome. However, there was a paucity of data on the societal costs or the healthcare burden of NASH with only one meta-analysis reporting on the direct costs of NASH \[[@CR63]\].

Advanced fibrosis progression was associated with significant increases in costs \[[@CR63]\]. In all stages of NASH, direct medical costs were reported to be high using prevalence-based simulation modelling techniques: in 2016 the total burden was estimated to be \$103 billion per year in the USA versus €27.7 billion in France, Germany and Italy together and £5.24 billion in the UK \[[@CR63]\]. NASH patients with compensated cirrhosis presented the highest direct cost burden compared to patients in other stages of NASH, highlighting the cost burden of advanced NASH progression.

Direct medical costs were also examined per age group, with total costs highest in patients aged 45--65, mirroring the disease prevalence \[[@CR63]\]. However, per patient costs were reported as highest in the 65+ age group, reflecting the higher proportion of patients in advanced fibrosis and HCC, and the increased burden of comorbidities \[[@CR63]\]. A USA SLR and model confirmed the high economic burden of NASH, reporting that the total cost of NASH-related care in North America will amount to \$593 billion between 2013 and 2033 \[[@CR30]\].

Lastly, a USA database analysis reported on high costs of NASH hospitalizations, with hospitalizations related to CVD incurring a longer stay and higher associated financial cost compared to NAFLD hospitalizations unrelated to CVD (length of stay was 6.5 versus 5.3 days, *p* \< 0.001; hospitalization cost was \$57,534 versus \$44,007, *p* \< 0.001) \[[@CR52], [@CR70]\].

Discussion {#Sec19}
==========

To the authors' knowledge, this structured literature review is the first broad-ranging examination of the NASH epidemiology, BoD literature, QoL and economic burden literature. In total, 53 publications were included in this review, with a significant paucity of data observed across all aspects of NASH epidemiology. The publications presented varying study designs and methodologies; the majority of the publications were small cohort studies (sample sizes of less than or equal to 100) and narrative reviews with undefined methodologies, while only a few publications employed a robust systematic approach. As a result, comparison of the results was difficult. Eight SLRs were captured in this review; however, only two examined the BoD in NASH \[[@CR19], [@CR25], [@CR30], [@CR31], [@CR33], [@CR46], [@CR47], [@CR49]\]. The high impact BoD SLR and meta-analysis study by Younossi et al. was underpinned by a model forecasting NASH prevalence and incidence \[[@CR19]\]. The other BoD SLR by Sanyal et al. presented limited information on NASH prevalence, comorbidities and economic burden as the study was only available in abstract form \[[@CR30]\]. Compared to the available literature identified, the current structured literature review provides a robust methodology and a more recent examination of data, with a broader scope, including NASH QoL and disease progression.

NASH was estimated to account for 3--5% of the global population, and approximately 60% of biopsied NAFLD patients \[[@CR19]--[@CR29]\]. Prevalence data are essential in understanding the size of current and future NASH populations; however, the captured publications presented a range of prevalence data, likely due to the varying publication focus and robustness of the methodologies used. Over half of the captured publications employed a narrative review approach and most did not specify the methodology used, reflecting the poor quality of these publications.

As a result of the unreliability of liver biopsy in diagnosing NASH and its association with high costs and invasive nature, especially in the general population, NASH prevalence data cannot be retrieved accurately and were frequently estimated \[[@CR14]\]. Validated 'histological' NASH score, data from annual health checks, national health surveys, and autopsy results were used in the identified publications to estimate the prevalence of NASH; however, these data can be fragmented and subject to selection bias, specifically in higher burden population, who likely also have one or more comorbid conditions, e.g. advanced fibrosis patients will likely have a higher instance of obesity and CVD compared to mild fibrosis patients. To ensure that accurate prevalence data are obtained not only from patients but also from the general public, an accurate, non-invasive and cost-effective screening tool is needed. For instance, ultrasound screening has emerged as a promising screening technique that is non-invasive, accurate and widely available \[[@CR31], [@CR67]--[@CR69], [@CR71]\]. Blood-based biomarkers have also emerged as a promising diagnostic alternative in NASH as they are non-invasive, have rapid turnaround times and pose limited risks to patients \[[@CR72]\]. More research on biomarkers in NASH is needed to determine if these markers accurately reflect disease progression in NASH and can be implemented in clinical practice \[[@CR72]\].

The global burden of NASH is high, with clinical consequences extending beyond the liver. Approximately 80% of NASH patients suffer from at least one comorbidity, with obesity, diabetes and CVD being the most common \[[@CR19]\]. While it is unclear to what extent NASH development is linked to these conditions, it is clear that NASH association with these comorbidities increases both the patient and healthcare burden \[[@CR19], [@CR21], [@CR22], [@CR24], [@CR28]--[@CR30], [@CR32]--[@CR42]\]. Despite this, the specific prevalence of comorbidities in NASH remains unclear with substantial discrepancies in the literature, specifically in sub-populations, such as in obese, morbidly obese, or bariatric surgery patients. For instance, NASH prevalence in a diabetic population was 14.5% in one study, and between 63% and 87% in a different study on the diabetic population \[[@CR41], [@CR42]\]. This can be due to several reasons, e.g. different baseline populations, or different definitions of how NASH is estimated/measured. Specifically, the varied focus of the publications was a key factor in the discrepancies noted, and a selection bias could have affected these results. This was further compounded by the robustness of the methodologies used, as the majority of the publications consisted of small cohort or observational studies.

On the basis of the current evidence base, it is unclear whether the BoD in NASH stems primarily from comorbidities or from NASH directly. For example, when comparing the QoL in patients with NASH, of which 27% have diabetes and 28% had bridging fibrosis or cirrhosis, to diabetic patients alone, the SF-36 PCS scores of patients with NASH and diabetes (mean 44.5) are lower than those with diabetes (mean 49.8), suggesting that the disease severity is worse in NASH and that comorbidities add to the overall burden of disease \[[@CR59], [@CR73]\]. However, when comparing the QoL in patients with NASH, of which 19% had diabetes and 37% had hypertension, to heart failure patients alone, the SF-36 PCS scores (mean 44.2) are higher than for those with heart failure (mean 36.5), suggesting that the burden of NASH is mostly dependent on the comorbidities \[[@CR60], [@CR74]\]. As a result of the limited QoL data in NASH patients and the different patient populations described, the true role of comorbidities in NASH BoD remains unclear. Further research is required to clarify the relationship between NASH and its comorbidities before firm conclusions can be drawn.

Despite the limited conclusions gathered from the literature on comorbidities in NASH, data on NASH progression were numerous \[[@CR19]--[@CR23], [@CR26]--[@CR28], [@CR35], [@CR37], [@CR45]--[@CR58]\]. The results clearly showed that NASH with advanced fibrosis significantly increases the likelihood of further progression to cirrhosis and HCC, with one in five NASH patients developing cirrhosis and/or HCC. While mild fibrosis (F1/F2) frequently presents with nonspecific symptoms and low disease burden, advanced fibrosis (F3/F4) exponentially reduces survival and increases liver-related mortality, with an approximately sevenfold increase in mortality rate in NASH compared to NAFLD \[[@CR50], [@CR55]\]. NASH, specifically NASH with advancing fibrosis, therefore presents itself as a clear target for future pharmacological therapies aiming at reducing the burden of NAFLD and its complications. Despite this, not all published literature is in agreement that NASH should be the main target of NAFLD therapy: a recent retrospective study of 60 NAFLD patient biopsies by Hagström et al. reported that baseline steatohepatitis was not associated with an increased risk for fibrosis progression in NAFLD and that fibrosis progression can occur in NAFLD patients without steatohepatitis \[[@CR75]\]. In contrast, a multinational prospective study of 458 NAFLD patients by Vilar-Gomez et al. reported that steatosis is significantly associated with a higher risk of death and liver-related complications, which aligns with the findings of this review, showcasing that NASH is associated with a significant burden and poor long-term prognosis \[[@CR76]\]. It is important to note that because the exact cause of NAFLD and NASH is not yet understood, it is difficult to accurately assess the underlying factors for progression \[[@CR5]--[@CR7]\]. Therefore, further research into the cause of this disease is recommended to improve our understanding of disease progression and the key factors at play.

Understanding of disease progression in NASH was impeded by the lack of consistency in fibrosis and cirrhosis stage terminology reported. Several terminologies were used in NASH staging, which were frequently unexplained in the publications and some appeared subjective, e.g. advanced cirrhosis, severe fibrosis and progressive fibrosis. Therefore, to ensure that the progression of NASH to a highly burdensome advanced fibrosis stage is clearly understood, a consensus on staging terminology is required. Correct terminology will allow for a clear quantification of the true disease burden of each step of this progressive disease and supports the development of effective therapies, specifically in advancing fibrosis, which has presented itself as a key determinant of disease progression and mortality \[[@CR46]\].

There was a significant lack of NASH QoL data, with only three publications reporting on PROs in NASH \[[@CR59]--[@CR61]\]. NASH patients reported significantly poorer physical and mental health, impacting the quality of their daily lives \[[@CR59], [@CR60]\]. Only the SF-36 health survey and CLDQ were reported, with standardized liver disease PROs, such as CLDQ, considered most appropriate. In order to truly understand the burden of this disease, however, patient-relevant outcomes, as well as clinical outcomes, must be further researched.

NASH-specific economic burden data, and especially in relation to direct costs of NASH, were lacking in the literature \[[@CR30], [@CR63], [@CR70]\]. The most prevalent economic data described NASH screening and treatment strategies, indicating an interest in new diagnostic tools and appropriate therapies, but a lack of research into their exact costs. The publications that investigated direct costs of NASH reported that, despite presenting with little or no symptoms, NASH association with comorbidities and its progressive nature significantly impacts healthcare systems in terms of costs. One meta-analysis reported that disease progression to cirrhosis and beyond was associated with significant increases in costs \[[@CR63]\]. Additionally, NASH cirrhosis patients exhibited significantly higher rates of hospitalizations compared with other cirrhosis etiologies. While several publications briefly reported on the economic burden of NASH specifically, few reported explicit costs. When costs were reported, they were not defined, e.g. "direct costs" were used but no clarification of what these costs included was provided. This is likely because there are little patient-level data available and cost databases frequently do not report NASH diagnosis, rather reporting liver disease or NAFLD with fibrosis or cirrhosis. This makes any information on NASH costs difficult to establish or compare; thus, the exact economic burden of NASH remains unclear.

Therapy options in NASH were not a focus of this review, and very few papers specifically looking at the economic impact of management options were retrieved. This is likely a reflection of no licensed drugs currently being available for NASH. At present, NASH management is varied and many off-label treatment options are being utilised in routine practice \[[@CR77]--[@CR81]\]. Current treatment focuses primarily on lifestyle modification and disease management, including weight loss, dietary modifications, exercise and managing comorbidities \[[@CR79]--[@CR81]\]. Many investigational treatments are being researched with more than 150 interventional studies currently ongoing (as described by clinicaltrials.gov) \[[@CR82]\]. Although advanced fibrosis is associated with the highest morbidity and mortality burden in NASH, there is a lack of treatments targeting NASH patients with advanced fibrosis with only two current therapies showing improvements in this population \[[@CR81]\]. Further investigational therapies are needed for NASH with advanced fibrosis, given that the majority of the available and upcoming NASH therapies are primarily focused on patients with mild-to-moderate fibrosis \[[@CR81]\].

Limitations {#Sec20}
-----------

A number of limitations were noted during the course of this structured literature review. The focus of this review was the NASH population, and as such the NAFLD population was not explicitly included in the search strategy. As NASH is the progressive phenotype of NAFLD, it is likely that some NAFLD publications with NASH information were excluded on the basis of this criterion. However, as publications reporting on NASH by name (even as part of the larger NAFLD population) were included, excluded publications would have likely not focused on NASH and may not have presented any discrete results other than for the overall NAFLD population.

Another limitation was the restriction of this structured review to English language publications. Despite a third of the included publications reporting data on non-English speaking countries, it is possible that some eligible publications were not captured because of this exclusion.

Additionally, a sparse evidence base was found across all stages of NASH, with several limitations identified in the captured literature. The publications consisted of generally poor-quality small studies, with short follow-up times, lack of consistency in describing NASH staging, variations in individual study aims, highly selective populations or differing geographies. As NASH is frequently reported as part of the wider NAFLD burden and is often not clearly distinguished from NAFLD, this may explain the small amount of studies focusing on NASH specifically and the poor quality of the literature identified in this review.

Conclusion {#Sec21}
==========

This first broad-ranging structured examination of the NASH literature revealed a paucity of evidence, which likely reflects the absence of approved therapies. As a result of its nonspecific symptoms and progressive nature, NASH remains underdiagnosed and poorly understood despite its high patient burden. Fibrosis is the key prognostic factor in NASH, with a worse prognosis observed in advanced fibrosis. The overwhelming impact of advanced fibrosis on patients and healthcare systems is evident. There is a clear need for early detection in NASH, particularly among symptomatic patients, along with the need for lifestyle modifications alongside new therapies. Important knowledge gaps remain in the literature, including a clear understanding of NASH progression and its association with comorbidities, NASH patient QoL and NASH-specific economic burden. Further robust quality evidence, specifically real-world and clinical trial data, is needed to improve our understanding of NASH, especially as fibrosis stages advance and NASH burden increases. This will inform the development of effective therapies in NASH and improve the management of this highly burdensome disease.
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